1. Home
  2. AIM vs PALT Comparison

AIM vs PALT Comparison

Compare AIM & PALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AIM
  • PALT
  • Stock Information
  • Founded
  • AIM 1966
  • PALT 1998
  • Country
  • AIM United States
  • PALT United States
  • Employees
  • AIM N/A
  • PALT N/A
  • Industry
  • AIM Biotechnology: Biological Products (No Diagnostic Substances)
  • PALT EDP Services
  • Sector
  • AIM Health Care
  • PALT Technology
  • Exchange
  • AIM Nasdaq
  • PALT Nasdaq
  • Market Cap
  • AIM 15.9M
  • PALT 16.7M
  • IPO Year
  • AIM N/A
  • PALT N/A
  • Fundamental
  • Price
  • AIM $0.20
  • PALT $1.70
  • Analyst Decision
  • AIM Strong Buy
  • PALT Hold
  • Analyst Count
  • AIM 2
  • PALT 1
  • Target Price
  • AIM $2.75
  • PALT N/A
  • AVG Volume (30 Days)
  • AIM 403.8K
  • PALT 25.9K
  • Earning Date
  • AIM 11-15-2024
  • PALT 11-12-2024
  • Dividend Yield
  • AIM N/A
  • PALT N/A
  • EPS Growth
  • AIM N/A
  • PALT N/A
  • EPS
  • AIM N/A
  • PALT N/A
  • Revenue
  • AIM $190,000.00
  • PALT $9,635,475.00
  • Revenue This Year
  • AIM N/A
  • PALT N/A
  • Revenue Next Year
  • AIM $1,086.80
  • PALT N/A
  • P/E Ratio
  • AIM N/A
  • PALT N/A
  • Revenue Growth
  • AIM N/A
  • PALT N/A
  • 52 Week Low
  • AIM $0.16
  • PALT $1.67
  • 52 Week High
  • AIM $0.62
  • PALT $5.50
  • Technical
  • Relative Strength Index (RSI)
  • AIM 40.44
  • PALT 37.27
  • Support Level
  • AIM $0.20
  • PALT $1.78
  • Resistance Level
  • AIM $0.23
  • PALT $2.00
  • Average True Range (ATR)
  • AIM 0.02
  • PALT 0.11
  • MACD
  • AIM 0.00
  • PALT -0.00
  • Stochastic Oscillator
  • AIM 10.75
  • PALT 8.11

About AIM AIM ImmunoTech Inc.

AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.

About PALT Paltalk Inc.

Paltalk Inc is a communications software innovator. It operates a network of consumer applications where users can meet, see, chat, broadcast and message in real-time in a secure environment with others in the network. The company's product portfolio includes Paltalk, Camfrog, Tinychat and Vumber. Its consumer applications generate revenue principally from subscription fees and advertising arrangements. The company's majority revenue is generated from live video chat products that are :Paltalk and Camfrog.

Share on Social Networks: